Lineage Cell Therapeutics, Inc. Quarterly Common Stock, Shares, Outstanding from Q4 2010 to Q2 2024

Taxonomy & unit
us-gaap: shares
Description
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
Summary
Lineage Cell Therapeutics, Inc. quarterly Common Stock, Shares, Outstanding history and growth rate from Q4 2010 to Q2 2024.
  • Lineage Cell Therapeutics, Inc. Common Stock, Shares, Outstanding for the quarter ending June 30, 2024 was 189M shares, a 8.25% increase year-over-year.
Common Stock, Shares, Outstanding, Quarterly (shares)
Common Stock, Shares, Outstanding, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 189M +14.4M +8.25% Jun 30, 2024 10-Q 2024-08-08
Q1 2024 189M +18.6M +10.9% Mar 31, 2024 10-Q 2024-05-09
Q4 2023 175M +4.89M +2.88% Dec 31, 2023 10-Q 2024-08-08
Q3 2023 175M +5.1M +3% Sep 30, 2023 10-Q 2023-11-09
Q2 2023 174M +4.69M +2.76% Jun 30, 2023 10-Q 2023-08-10
Q1 2023 170M +446K +0.26% Mar 31, 2023 10-Q 2023-05-11
Q4 2022 170M +616K +0.36% Dec 31, 2022 10-K 2024-03-07
Q3 2022 170M +1.42M +0.84% Sep 30, 2022 10-Q 2022-11-10
Q2 2022 170M +2.71M +1.62% Jun 30, 2022 10-Q 2022-08-11
Q1 2022 170M +7.66M +4.73% Mar 31, 2022 10-Q 2022-05-12
Q4 2021 169M +16.4M +10.7% Dec 31, 2021 10-K 2023-03-09
Q3 2021 168M +18.5M +12.3% Sep 30, 2021 10-Q 2021-11-10
Q2 2021 167M +17.2M +11.5% Jun 30, 2021 10-Q 2021-08-12
Q1 2021 162M +12.2M +8.18% Mar 31, 2021 10-Q 2021-05-13
Q4 2020 153M +3.29M +2.2% Dec 31, 2020 10-K 2022-03-10
Q3 2020 150M +201K +0.13% Sep 30, 2020 10-Q 2020-11-04
Q2 2020 150M +188K +0.13% Jun 30, 2020 10-Q 2020-08-06
Q1 2020 150M +430K +0.29% Mar 31, 2020 10-Q 2020-05-07
Q4 2019 150M +22.7M +17.8% Dec 31, 2019 10-K 2021-03-11
Q3 2019 150M +22.9M +18.1% Sep 30, 2019 10-Q 2019-11-12
Q2 2019 150M +22.8M +17.9% Jun 30, 2019 10-Q 2019-08-08
Q1 2019 149M +22.5M +17.8% Mar 31, 2019 10-Q 2019-05-09
Q4 2018 127M +270K +0.21% Dec 31, 2018 10-K 2020-03-12
Q3 2018 127M +11.1M +9.57% Sep 30, 2018 10-Q 2018-11-08
Q2 2018 127M +16M +14.4% Jun 30, 2018 10-Q 2018-08-02
Q1 2018 127M +16M +14.4% Mar 31, 2018 10-Q 2018-05-10
Q4 2017 127M +24.1M +23.4% Dec 31, 2017 10-K 2019-03-14
Q3 2017 116M +13M +12.7% Sep 30, 2017 10-Q 2017-11-09
Q2 2017 111M +9.21M +9.06% Jun 30, 2017 10-Q 2017-08-09
Q1 2017 111M +20.4M +22.6% Mar 31, 2017 10-Q 2017-05-10
Q4 2016 103M +12.4M +13.7% Dec 31, 2016 10-K 2018-03-15
Q3 2016 103M +20.7M +25.3% Sep 30, 2016 10-Q 2016-11-04
Q2 2016 102M +23.3M +29.7% Jun 30, 2016 10-Q 2016-08-09
Q1 2016 90.4M +12.1M +15.5% Mar 31, 2016 10-Q 2016-05-10
Q4 2015 90.4M +12.2M +15.6% Dec 31, 2015 10-K 2017-03-16
Q3 2015 82M +13.8M +20.1% Sep 30, 2015 10-Q 2015-11-09
Q2 2015 78.4M +11.5M +17.2% Jun 30, 2015 10-Q 2015-08-10
Q1 2015 78.3M +19.2M +32.6% Mar 31, 2015 10-Q 2015-05-08
Q4 2014 78.2M +21.5M +37.9% Dec 31, 2014 10-K 2016-03-15
Q3 2014 68.3M +12.7M +22.8% Sep 30, 2014 10-Q 2014-11-07
Q2 2014 66.9M +11.3M +20.2% Jun 30, 2014 10-Q 2014-08-11
Q1 2014 59.1M +6.52M +12.4% Mar 31, 2014 10-Q 2014-05-12
Q4 2013 56.7M +7.33M +14.8% Dec 31, 2013 10-K 2015-03-11
Q3 2013 55.6M +6.46M +13.1% Sep 30, 2013 10-Q 2013-11-12
Q2 2013 55.6M +6.11M +12.3% Jun 30, 2013 10-Q 2013-08-09
Q1 2013 52.6M +3.52M +7.17% Mar 31, 2013 10-Q 2013-05-10
Q4 2012 49.4M +347K +0.71% Dec 31, 2012 10-K 2014-03-17
Q3 2012 49.2M +211K +0.43% Sep 30, 2012 10-Q 2012-11-09
Q2 2012 49.5M +635K +1.3% Jun 30, 2012 10-Q 2012-08-09
Q1 2012 49M Mar 31, 2012 10-Q 2012-05-10
Q4 2011 49M +1.26M +2.63% Dec 31, 2011 10-K 2013-03-18
Q3 2011 49M Sep 30, 2011 10-Q 2011-11-08
Q2 2011 48.9M Jun 30, 2011 10-Q 2011-08-09
Q4 2010 47.8M Dec 31, 2010 10-K 2012-03-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.